Trial · NCT02909140
Optimal Method for Mydriasis in Cataract Surgery
NCT02909140, Not applicable, Terminated, Johns Hopkins University; results first posted 2019-09-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Optimal Method for Mydriasis in Cataract Surgery. Trials, record NCT02909140. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02909140
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Optimal Method for Mydriasis in Cataract Surgery
- NCT number
- NCT02909140
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 3 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Cataract
- Interventions
- Topical phenylephrine 2.5%, Topical cyclopentolate 1%, Intracameral Lidocaine 1%, Intracameral 0.2- 0.3ml of epinephrine 1:10,000
- First posted
- 2016-09-21
- Last updated
- 2019-09-10
- Results first posted
- 2019-09-10
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pupil Size Immediately Prior to Capsulorrhexis | Immediately prior to the capsulorrhexis step of cataract surgery | Pupil size immediately prior to the capsulorrhexis step of cataract surgery. This will be recorded by digital photography and measured by a researcher who is masked to the intervention. |
| Secondary | Pupil Size (mm) Immediately After Nuclear Disassembly | Immediately after nuclear disassembly step of cataract surgery | Pupil size immediately after breaking up of cataractous lens |
| Secondary | Pupil Size Immediately Prior to Intraocular Lens (IOL) Insertion | Immediately prior to IOL insertion step of cataract surgery | Pupil size after insertion of IOL lens |
| Secondary | Pupil Size Upon Completion of Surgery | intraoperative | |
| Secondary | Pupil Size on Post-operative Day 1 | Post-operative Day 1 | |
| Secondary | Percentage of Patients in Each Arm That Required Another Mydriatic Agent | intraoperative | |
| Secondary | Cumulative Energy Dispersed for Each Arm | During cataract surgery | The amount of energy needed to break up the cataractous lens |
| Secondary | Mean Time Taken to Perform Phacoemulsification in Each Arm | intraoperative | |
| Secondary | Percentage of Patients With an Increase in the Blood Pressure or Heart Rate | Baseline | |
| Secondary | Percentage of Patients With an Increase in the Blood Pressure or Heart Rate | intraoperative |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pupil Size Immediately Prior to Capsulorrhexis | Immediately prior to the capsulorrhexis step of cataract surgery | Data was only collected for the Intracameral Mydriasis' arm. We analyzed data for 1 participant only because of lack of data for the other participant. | mm | NUMBER |
| SECONDARY | Pupil Size (mm) Immediately After Nuclear Disassembly | Immediately after nuclear disassembly step of cataract surgery | Data was only collected for the Intracameral Mydriasis' arm. We analyzed data for 1 participant only because of lack of data for the other participant. | mm | NUMBER |
| SECONDARY | Pupil Size Immediately Prior to Intraocular Lens (IOL) Insertion | Immediately prior to IOL insertion step of cataract surgery | Data was only collected for the Intracameral Mydriasis' arm. We analyzed data for 1 participant only because of lack of data for the other participant. | mm | NUMBER |
| SECONDARY | Pupil Size Upon Completion of Surgery | intraoperative | Data was only collected for the Intracameral Mydriasis' arm. We analyzed data for 1 participant only because of lack of data for the other participant. | mm | NUMBER |
| SECONDARY | Pupil Size on Post-operative Day 1 | Post-operative Day 1 | Data not available because it wasn't collected | ||
| SECONDARY | Percentage of Patients in Each Arm That Required Another Mydriatic Agent | intraoperative | Data was only collected for the Intracameral Mydriasis' arm | percent of participants | NUMBER |
| SECONDARY | Cumulative Energy Dispersed for Each Arm | During cataract surgery | Data was only collected for the Intracameral Mydriasis' arm. We analyzed data for 1 participant only because of lack of data for the other participant. | Percent-seconds | NUMBER |
| SECONDARY | Mean Time Taken to Perform Phacoemulsification in Each Arm | intraoperative | Data was only collected for the Intracameral Mydriasis' arm. We analyzed data for 1 participant only because of lack of data for the other participant. | seconds | NUMBER |
| SECONDARY | Percentage of Patients With an Increase in the Blood Pressure or Heart Rate | Baseline | Data not available because data was not collected | ||
| SECONDARY | Percentage of Patients With an Increase in the Blood Pressure or Heart Rate | intraoperative | Data not available because data was not collected |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 outcomesResults by group9
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pupil Size Immediately Prior to Capsulorrhexis | Intracameral Mydriasis | 8 | mm | ||
| Pupil Size (mm) Immediately After Nuclear Disassembly | Intracameral Mydriasis | 8 | mm | ||
| Pupil Size Immediately Prior to Intraocular Lens (IOL) Insertion | Intracameral Mydriasis | 8 | mm | ||
| Pupil Size Upon Completion of Surgery | Intracameral Mydriasis | 7 | mm | ||
| Percentage of Patients in Each Arm That Required Another Mydriatic Agent | Intracameral Mydriasis | 0 | percent of participants | ||
| Cumulative Energy Dispersed for Each Arm | Intracameral Mydriasis | 6.6 | Percent-seconds | ||
| Mean Time Taken to Perform Phacoemulsification in Each Arm | Intracameral Mydriasis | 76 | seconds | ||
| Mean Time Taken to Perform Phacoemulsification | Intracameral Mydriasis | 76 | seconds | ||
| Percentage of Patients in Each Arm That Required Use of an Iris Expansion Device During the Procedure | Intracameral Mydriasis | 50 | percent |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Topical Mydriasis | 0 | |
| Overall Study | STARTED | Intracameral Mydriasis | 2 | |
| Overall Study | STARTED | Topical + Intracameral Mydriasis | 0 | |
| Overall Study | COMPLETED | Topical Mydriasis | 0 | |
| Overall Study | COMPLETED | Intracameral Mydriasis | 2 | |
| Overall Study | COMPLETED | Topical + Intracameral Mydriasis | 0 | |
| Overall Study | NOT COMPLETED | Topical Mydriasis | 0 | |
| Overall Study | NOT COMPLETED | Intracameral Mydriasis | 0 | |
| Overall Study | NOT COMPLETED | Topical + Intracameral Mydriasis | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Topical Mydriasis | 0 | 0 |
| Total, all-cause mortality | Intracameral Mydriasis | 0 | 2 |
| Total, all-cause mortality | Topical + Intracameral Mydriasis | 0 | 0 |
| Total, other adverse events | Topical Mydriasis | 0 | 0 |
| Total, other adverse events | Intracameral Mydriasis | 0 | 2 |
| Total, other adverse events | Topical + Intracameral Mydriasis | 0 | 0 |
| Total, serious adverse events | Topical Mydriasis | 0 | 0 |
| Total, serious adverse events | Intracameral Mydriasis | 0 | 2 |
| Total, serious adverse events | Topical + Intracameral Mydriasis | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02909140
GET https://conductscience.org/api/trials/v1/NCT02909140/registered